@rohankunk, please go through the annual report. They have talked about expansion plan in detail. There they have mentioned 4K 2k 2k 1k = 9k cr additional revenue…so they are projecting 10k cr revenue in 4-5 years.. there is also 12 ANDA approval in process. After ANDA approval profitability in API business will be like any other top pharma company which is 20-22%… so consider they achieve 70% of the projected numbers…7k cr revenue with 15% profit which would be EPS 15 (it can be higher as well)… so share price should reach ~500 in 4-5 years … they are going to add 16 billion USD market size new products in 2021-2022… so expect some blockbuster API announcement in next 6-9 months… I am not going to sell a single share …till 2026
12.34 AM Jun 12th
We take the quality of the messages posted on forum as seriously as our articles. Kindly follow our Code of Conduct and refrain from posting any abusive, promotional or gibberish content on forum.
Disclaimer : The views expressed in the forum are the views of the user writing the post, and not that of moneycontrol.com. You agree, by accessing this forum, that moneycontrol.com bears no liability for any posts on this forum or, any losses suffered by following any advice posted on this forum. moneycontrol.com operates this real time, open, unmoderated, private forum for users to exchange information and to discuss various investing techniques. moneycontrol.com or, its personnel do not post anything, or vet the content posted, on this forum. moneycontrol.com reserves the right to deny service to anyone. You, and not moneycontrol.com, assume the entire cost and risk of any trading you choose to undertake. You are solely responsible for making your own investment decisions. If you choose to engage in such transactions with or without seeking advice from a licensed and qualified financial advisor or entity, then such decision and any consequences flowing therefrom are your sole responsibility.